SYRS News and Press, Syros Pharmaceuticals Inc. From 05/09/21

Syros Pharmaceuticals, Inc. (SYRS) Q1 2021 Earnings Conference Call May 06, 2021, 08:30 AM ET Company Participants Naomi Aoki - VP, CC&IR Nancy Simonian - CEO David Roth - CMO Joe Ferra - CFO Eric Olson - CSO Conference Call Participants Phil Nadeau - Cowen & Company Jason Butler - JM...

Syros Pharmaceuticals (SYRS): Q1 GAAP EPS of -$0.23 beats by $0.24.Revenue of $4.83M (+102.9% Y/Y) beats by $2.16M.Shares +2.55% PM.Press Release For further details see: Syros Pharmaceuticals EPS beats by $0.24, beats on revenue

Enrolling Patients in Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Higher-Risk MDS Patients Today Announced Three-Part KOL Webinar Series on Its Portfolio of Investigational Targeted Hematology Therapies, Beginning May 2021 ...

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, May 6, 2021 to report its first quarter 2021 financial results and provid...

Shares of Syros Pharmaceuticals Inc. (NASDAQ:SYRS) traded today at $6.18, breaking its 52-week low. So far today approximately 278,000 shares have been exchanged, as compared to an average 30-day volume of 774,000 shares. Syros Pharmaceuticals Inc. has overhead space with shares priced $...

Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%. For further details see: KPTI, CENX, GMAB and TCRR among after-hours movers

It has been 10 months since we last looked at a developmental concern named Syros Pharmaceuticals and we promised we would keep an eye on developments. Today, we revisit Syros as it has been advancing its pipeline and has some trial milestones on the horizon. We update our investm...

The following slide deck was published by Syros Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Syros Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation

Syros Pharmaceuticals, Inc. (SYRS) Q4 2020 Earnings Conference Call March 4, 2021 8:30 AM ET Company Participants Naomi Aoki - Vice President, Corporate Communications and Investor Relations Nancy Simonian - Our Chief Executive Officer David Roth - Chief Medical Officer Joe Ferra - Chief Fina...

Syros Pharmaceuticals (SYRS): Q4 GAAP EPS of -$0.62 misses by $0.12.Revenue of $5.7M (+1017.6% Y/Y) beats by $3.01M.Press Release For further details see: Syros Pharmaceuticals EPS misses by $0.12, beats on revenue